Poster Session 3 – Wednesday, December 9, 2020: 8:00 AM CT
   
  Imaging
PS3-01 Quantitative Dynamic Contrast-Enhanced (DCE) MRI radiomic phenotypes for prediction of nodal and distal metastasis in breast cancer patients
Margishvili Rauch G, Drukker K, Elshafeey N, Mohamed RMM, Boge M, Adrada BE, Candelaria RP, Salama M, Shkatova I, Giger M, Yang WT. Breast and Abdominal imaging, The University of Texas MD Anderson Cancer Center, Houston, TX; Biological Sciences Division, Radiology The University of Chicago, Chicago, IL; Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX; Breast imaging, The University of Texas MD Anderson Cancer Center, Houston, TX; Diagnostic imaging, The University of Texas MD Anderson Cancer Center, Houston, TX; EHR Clinical Ancillaries, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Radiology, The University of Chicago, Chicago, IL.
PS3-02 Radiologic review to refine selection of candidates for de-escalation of neoadjuvant therapy
Onishi N, Li W, Venters SJ, Wolf DM, Newitt DC, Price ER, Gibbs J, LeStage B, the I-SPY 2 Pathology Working Group, the I-SPY 2 Imaging Working Group, the I-SPY 2 Consortium, Symman WF, Hylton NM. University of California, San Francisco, San Francisco, CA; I-SPY 2 Advocacy Group, San Francisco, CA; MD Anderson Cancer Center, Houston, TX.
PS3-03 [<sup>89</sup>Zr]-pertuzumab pet imaging reveals paclitaxel treatment efficacy is positively correlated with her2 expression in human breast cancer xenograft mouse models 
Lu Y, Massicano A, Song P, Li M, Lapi S, Sorace A. University of Alabama at Birmingham, Birmingham, AL.
PS3-04 Breast tumor targeted fluorescence guidance for intraoperative margin assessment
Tafreshi N, Budzevich M, Sun W, Mahadevan D, Lee MC, Morse DL. Dept. of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL; Small Animal Imaging Core, Moffitt Cancer Center and Research Institute, Tampa, FL; Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL; Dept. of Medicine, Division of Hematology and Medical Oncology, University of Texas, San Antonio, TX; Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL; Dept. of Cancer Physiology, Moffitt Cancer Center, Tampa, FL.
PS3-05 Value of [<sup>18</sup>F]-FES-PET to solve clinical dilemmas in breast cancer patients: a retrospective study
Boers J, Loudini N, Brunsch CL, Koza SA, de Vries EFJ, Glaudemans AWJM, Hospers GAP, Schröder CP. University Medical Center Groningen, Groningen, Netherlands.
PS3-06 Fluoroestradiol F18 positron emission tomography diagnostic performance to characterize estrogen receptor status in breast cancer
Webner P, Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Divgi C, Linden HM. Zionexa US Corporation, Fishers, IN; University of Pittsburgh, Pittsburgh, PA; Merlin Biomedical Consulting LLC, Hendersonville, NC; Divgi Consulting LLC, Meadowbrook, PA; University of Washington, Seattle, WA.
PS3-07 Molecular imaging of hypoxia and granzyme B alterations during combination treatment with immunotherapy in triple negative breast cancer
Napier TS, Hunter CL, Song PN, Larimer BM, Sorace AG. University of Alabama at Birmingham, Birmingham, AL.
PS3-08 Assessment of early response to neoadjuvant systemic therapy (NAST) of triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: a pilot study
Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RMM, Abdelhafez AH, Son JM, Sun J, Elshafeey NA, White JB, Lane DL, Leung JWT, Scoggins ME, Spak DA, Arribas E, Ravenberg E, Santiago L, Moseley TW, Whitman GJ, Le-Petross H, Musall BC, Miyoshi M, Wang X, Willis B, Hash S, Kotrotsou A, Wei P, Hwang K-P, Thompson A, Moulder SL, Candelaria RP, Yang W, Ma J, Pagel MD. UT MD Anderson Cancer Center, Houston, TX; GE Healthcare Japan, Tokyo, Japan; GE Healthcare, Houston, TX; Baylor College of Medicine, Houston, TX.
PS3-09 The use of magnetic resonance imaging (MRI) in predicting pathological complete response(pCR) in the breast and axilla after the addition of immunotherapy to neoadjuvant systemic therapy (NST)
Rajarajan N, Segarra D, Weinfurtner RJ, Lopez AA, Lee MC, Kiluk J, Soliman H, Khong H, Hyo HS, Rosa M, Czerniecki BJ, Khakpour N. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; USF Health Morsani College of Medicine, Tampa, FL.
PS3-10 Monitoring neoadjuvant chemotherapy using diffuse optical tomography breast imaging system
Altoe ML, Kalinsky K, Guo H, Hibshoosh H, Tejada M, Crew KD, Accordino MK, Trivedi M, Marone A, Kim HK, Hielscher AH, Hershman DL. Columbia University, New York, NY.
PS3-11 Correlation of pathological complete response and radiological response with Contrast-enhanced mammography in breast cancer patients after neoadjuvant chemotherapy
Llabrés Valentí E, Antela López JC, Cejuela Solís M, Gómez de Liaño A, Vega Benítez V, Pavcovich M, Jimenez Medina C, Aranda Sánchez JJ, Reyes Rodriguez I, Cazorla Betancor M, Galan Garcia ME, Tejera Hernández AA, Pérez Correa P, Junquera Rionda P, Ramchandani Vaswani A, Rubio EV. Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain.
PS3-12 Prediction of pathological complete response to neoadjuvant chemotherapy in early triple negative breast cancer patients by serial breast ultrasound examination
Rapoport B, Smit T, Heyman L, Moosa F, Benn CA. The Medical Oncology Centre of Rosebank, Johannesburg, South Africa; Netcare Breast Care Centre, Johannesburg, South Africa.
PS3-13 Non-invasive screening for breast cancer risk based on circulating ensembles of tumor associated cells
Akolkar D, Patel D, Apurwa S, Pawar S, Bodke H, Ranjan V, Chougule R, Shejwalkar P, Khan S, Dhasarathan R, Devhare P, Patil S, Datta V, Sims C, Schuster S, Bhatia J, Bose C, Srinivasan A, Datar R. Datar Cancer Genetics, Nasik, India; Datar Cancer Genetics Europe GmbH, Bayreuth, Germany.
PS3-14 Assessment of clip locations on breast MRI during NAC to guide tumor bed biopsy at mid-treatment
Bareng TJ, Gibbs J, Li W, Onishi N, Joe BN, Price E, LeStage B, Crespo C, I-SPY 2 Imaging Working Group, I-SPY 2 Consortium, Hylton NM. University of California, San Francisco, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Duke University, Durham, NC.
PS3-15 Imaging of the distribution of human breast ducts
Love SM, Klock J, Wiskin J. Dr Susan Love Research Foundation, Encino, CA; QT Ultrasound, Novato, CA.
PS3-16 Identifying the most relevant descriptors when evaluating ultrasound images in breast cancer diagnostics: A secondary analysis of an international multicenter trial
Pfob A, Barr RG, Duda V, Buesch C, Heil J, Golatta M. Breast Unit, Heidelberg University, Heidelberg, Germany; Department of Radiology, Northeastern Ohio Medical University, Rootstown, OH; Breast Unit, Philipps University of Marburg, Marburg, Germany; Institute of Medical Biometry and Informatics (IMBI), University of Heidelberg, Heidelberg, Germany.
PS3-17 Patient and Provider Determinants of breast cancer screening among Ontario women age 40-49: a population based retrospective cohort study
Nadler MB, Marchand-Austin A, Austin PC, Desnoyers A, Wilson BE, Lofters A, Ivers N, Amir E. Princess Margaret Cancer Centre & University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences (ICES), Toronto, ON, Canada; Women’s College Research Institute & Department of Family and Community Medicine, Women’s College Hospital, Toronto, ON, Canada.
PS3-18 Differences in the diagnostic performance of breast ultrasound with or without additional patient information: A secondary analysis of an international multicenter trial
Pfob A, Barr RG, Duda V, Buesch C, Heil J, Golatta M. Breast Uni, Heidelberg University, Heidelberg, Germany; Department of Radiology, Northeastern Ohio Medical University, Rootstown, OH; Breast Unit, Philipps University of Marburg, Marburg, Germany; Institute of Medical Biometry and Informatics (IMBI), University of Heidelberg, Heidelberg, Germany.
PS3-19 Prognostic value of textural associated with metabolic parameters of baseline <sup>18</sup>FDG-PET/CT in early triple-negative breast cancer (TNBC)
Bouron C, Mathie C, Seegers V, Guillerminet C, Campone M, Morel O, Jézéquel P, Patsouris A, Testard A. CHU Angers, Angers, France; ICO Paul Papin, Angers, France; ICO René Gauducheau, Nantes, France.
PS3-20 Rapid beside diagnosis of breast core needle biopsies using stimulated raman histology
Orringer DA, Chen T, Pastore S, Darvishian F, Toth H, Schnabel F. NYU Langone Health, New York, NY; Invenio Imaging, Santa Clara, NY.
PS3-21 Predicting cardiac dysfunction in breast cancer patients undergoing aromatase inhibitor treatment using biomechanical model-based elasticity imaging
Miller CE, Jordan J, Thomas A, Weis J. Wake Forest University, Winston-Salem, NC; Virginia Commonwealth University, Richmond, VA; Wake Forest Baptist Medical Center, Winston-Salem, NC.
PS3-22 A new computational model for visualization and prediction of breast cancer growth based on reinforcement learning
Zangooei MH, Margolis R, Hoyt K. University of Texas at Dallas, Richardson, TX.
PS3-23 Experience of contrast-enhanced mammography in patients with breast augmentation surgery
Carnahan M, Pockaj B, Pizzitola V, Giurescu M, Lorans R, Eversman W, Sharpe R, Cronin P, Northfelt D, Anderson K, Ernst B, Patel B. Mayo Clinic-Arizona, Phoenix, AZ.
PS3-24 Using Big Data to gauge effectiveness of Breast Cancer Awareness Month
Gathers DA, Pankratz VS, Tawfik B. The University of New Mexico Health Sciences Center, Albuquerque, NM.
PS3-25 Quantitation of serum thioredoxin 1 could mitigate difficulty to detect breast cancer from dense breasts by mammography
Casas A, Ciruelos E, Oliveira M, Saura C, Bellet M, Pernas S, Gavilá J, Muñoz M, Vidal M, Gonzalez Farré B, Cejalvo JM, Lopez R, Vivancos A, Scaltriti M, Bofill JS, Blancas I, Alba E, Boni V, De la Cruz S, Galve E, Perelló A, Margelí M, Canes J, Céliz P, Masanas H, Olmos R, Fonts M, Fernandez-Pascual P, Villagrasa P, Prat A. Fundación Actitud Frente al Cáncer / SOLTI Breast Cancer Research Group, Sevilla / Barcelona, Spain; Hospital 12 de Octubre / SOLTI Breast Cancer Research Group, Madrid / Barcelona, Spain; Vall d' Hebron University Hospital / Vall d’Hebron Institute of Oncology / SOLTI Breast Cancer Research Group, Barcelona, Spain; Institut Catala d’ Oncologia Hospitalet / SOLTI Breast Cancer Research Group, Barcelona, Spain; Instituto Valenciano de Oncología / SOLTI Breast Cancer Research Group, Valencia / Barcelona, Spain; Hospital Clinic de Barcelona / SOLTI Breast Cancer Research Group, Barcelona, Spain; Hospital Clinic de Barcelona, Barcelona, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Complejo Universitario Santiago de Compostela, Santiago de Compostela, Spain; Vall d’Hebron Institute of Oncology, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Hospital Virgen del Rocío, Sevilla, Spain; Hospital Universitario San Cecilio de Granada / Hospital Virgen del Rocío, Granada / Sevilla, Spain; Hospital Clínico Universitario Virgen de la Victoria, Malaga, Spain; Centro Integral Oncológico Clara Campal, Madrid, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain; Hospital de Basurto, Bilbao, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; Hospital Germans Trias I Pujol, Badalona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Fundación Cáncer de Mama Metastásico, Spain, Spain.
PS3-26 Characterizing errors in perfusion model parameters derived from retrospectively abbreviated quantitative DCE-MRI data
Slavkova KP, DiCarlo JC, Syed AK, Wu C, Virostko J, Sorace AG, Yankeelov TE. University of Texas at Austin, Austin, TX; University of Alabama at Birmingham, Birmingham, AL.
PS3-27 18f-fdg-pet/ct and mri in the assessment of neoadjuvant chemotherapy treatment response in breast cancer. correlation with pathological response 
Guarin M, Azar ME, Tinetti C, Mansilla MD, Namias M, Carballo P, Santamarina L, Cavallero J, Moreau R, Gonzalez C, Caceres V, Gonzalez E, Bruno G. Fundacion Centro Diagnostico Nuclear, Buenos Aires, Argentina; Instituto de Oncologia Angel H. Roffo, Buenos Aires, Argentina.
PS3-28 Three-dimensional H-scan ultrasound imaging for acute detection of breast cancer response to neoadjuvant treatment - initial results using a preclinical animal model
Tai H, Reddy S, Song J, Khairalseed M, Hoyt K. University of Texas at Dallas, Richardson, TX.
PS3-29 Pixel-level tissue classification from ultrasound images of breast cancer and direct comparison to matched histological measurements
Khairalseed M, Reddy S, Song J, Rijal G, Hoyt K. University of Texas at Dallas, Richardson, TX.
PS3-30 Peri-operative diagnostic accuracy of magnetic resonance imaging and ultrasonography in breast cancer: a meta-analysis
Mouabbi JA, Sako Z, Abdalla A, Hadid T, Rimawi MF. Baylor College of Medicine, Houston, TX; Ascension St John Hospital, Detroit, MI.